title: Role of HDL in those with diabetes.
abstract: Low levels of high-density lipoprotein cholesterol (HDL-C) have been associated with an increased risk of coronary heart disease in prospective population studies and clinical trials of high-risk patients treated with a low to moderate intensity statin. As a result, therapeutic targets were developed to increase concentrations of HDL-C. Subsequently, clinical trials of high-intensity statins have not supported this previously well-established association. In trials of high-intensity statin therapy, low HDL particle concentration (HDL-P) has been associated with an increased risk of future cardiovascular events. Therefore, strategies that increase HDL-C without expanding the pool of HDL-P with its rich proteome/lipidome do not seem to be an effective strategy. In this review, we discuss potential mechanisms of action for the anti-atherogenic effect of HDL and the impact of current and emerging therapies on the functional capacity of HDL-P. Finally, we discuss emerging therapies that increase the concentration and functional properties of HDL.
authors.forename: Carlos G
authors.initials: CG
authors.lastname: Santos-Gallego
authors.forename: Robert S
authors.initials: RS
authors.lastname: Rosenson
mesh_terms: D050197:Atherosclerosis / Q000150:complications / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000150:complications / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism*; D048909:Diabetes Complications / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000378:metabolism*; D005081:Exercise Therapy; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use; D058607:Fibric Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D052456:Hypoalphalipoproteinemias / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use; D016540:Smoking Cessation; D061217:Weight Reduction Programs
chemical_list: D008076:Cholesterol, HDL; D005231:Fatty Acids, Unsaturated; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin